menu
menu
Breast Cancer
Sunil S. Badve, MD, FRCPath and Manali Bhave, MD
This podcast from ASCP will highlight important and practice-changing developments related to Ki67 testing, including the standardization, interpretation of findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.
Swikrity U. Baskota, MD; Marilyn Bui, MD, PhD; Mamatha Chivukula, MD, FASCP; Joseph Kim, MD, MBA, MPH, CPHQ
During this recorded 2022 ASCP Annual Meeting session, a moderated expert faculty panel discussed evolving and emerging trends in breast cancer classification and reporting across the HER2+ spectrum. They also discussed how pathologists and laboratory professionals can prepare for HER2-low classification, tracking, and reporting. In addition, they reviewed some of the current challenges in HER2 testing and explored opportunities to prepare for the future landscape of HER classification in breast cancer.
Ali Brown, MD, FASCP; Erinn Downs-Kelly, DO; Aysegul A. Sahin, MD
This podcast from ASCP will help you understand current guidelines for scoring HER2 IHC and factors that may affect IHC performance, updated scoring for HER2 ISH, HER2 heterogeneity and HER2-low tumors, and practical applications of HER2 scoring and reporting challenges.
Ali Brown, MD, FASCP; Erinn Downs-Kelly, DO; Aysegul A. Sahin, MD
This podcast from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.